1
|
Wang M, Zhang Y, Cai X, Yang S, Sun S, Zhou S, Lv W, Du N, Li Y, Ma C, Ren K, Liu M, Tang B, Wang A, Chen X, Li P, Lv K, Zheng Z. Exploration and structure-activity relationship research of benzenesulfonamide derivatives as potent TRPV4 inhibitors for treating acute lung injury. Bioorg Chem 2024; 147:107396. [PMID: 38705108 DOI: 10.1016/j.bioorg.2024.107396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2024] [Revised: 04/11/2024] [Accepted: 04/23/2024] [Indexed: 05/07/2024]
Abstract
RN-9893, a TRPV4 antagonist identified by Renovis Inc., showcased notable inhibition of TRPV4 channels. This research involved synthesizing and evaluating three series of RN-9893 analogues for their TRPV4 inhibitory efficacy. Notably, compounds 1b and 1f displayed a 2.9 to 4.5-fold increase in inhibitory potency against TRPV4 (IC50 = 0.71 ± 0.21 μM and 0.46 ± 0.08 μM, respectively) in vitro, in comparison to RN-9893 (IC50 = 2.07 ± 0.90 μM). Both compounds also significantly outperformed RN-9893 in TRPV4 current inhibition rates (87.6 % and 83.2 % at 10 μM, against RN-9893's 49.4 %). For the first time, these RN-9893 analogues were profiled in an in vivo mouse model, where intraperitoneal injections of 1b or 1f at 10 mg/kg notably mitigated symptoms of acute lung injury induced by lipopolysaccharide (LPS). These outcomes indicate that compounds 1b and 1f are promising candidates for acute lung injury treatment.
Collapse
Affiliation(s)
- Mengyuan Wang
- Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China
| | - Yuehao Zhang
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; Department of Pharmaceutical Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China
| | - Xu Cai
- National Engineering Research Center for Strategic Drugs, Beijing Institute of Pharmacology and Toxicology Institution, Beijing 100850, China
| | - Shangze Yang
- Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China
| | - Shiyang Sun
- National Engineering Research Center for Strategic Drugs, Beijing Institute of Pharmacology and Toxicology Institution, Beijing 100850, China
| | - Sheng Zhou
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; Department of Pharmaceutical Chemistry, School of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China
| | - Weizhen Lv
- Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China
| | - Na Du
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Yan Li
- Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China
| | - Chao Ma
- MindRank AI Ltd., Hangzhou 310000, China
| | - Kexin Ren
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Mingliang Liu
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Bowen Tang
- MindRank AI Ltd., Hangzhou 310000, China
| | - Apeng Wang
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Xingjuan Chen
- Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China.
| | - Pengyun Li
- National Engineering Research Center for Strategic Drugs, Beijing Institute of Pharmacology and Toxicology Institution, Beijing 100850, China.
| | - Kai Lv
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
| | - Zhibing Zheng
- National Engineering Research Center for Strategic Drugs, Beijing Institute of Pharmacology and Toxicology Institution, Beijing 100850, China
| |
Collapse
|
3
|
Lawhorn BG, Brnardic EJ, Behm DJ. Recent advances in TRPV4 agonists and antagonists. Bioorg Med Chem Lett 2020; 30:127022. [PMID: 32063431 DOI: 10.1016/j.bmcl.2020.127022] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2020] [Accepted: 02/05/2020] [Indexed: 01/03/2023]
Abstract
TRPV4 is a ubiquitously expressed, non-selective cation channel activated by a range of stimuli including hypotonicity, temperature, pH, stretch and endogenous ligands. Agents that modulate TRPV4 are sought as potential therapeutics for the treatment of many diseases including osteoarthritis, respiratory illnesses, gastrointestinal disorders, pain and congestive heart failure. In recent years, significant advances in TRPV4 drug discovery have been realized as at least seven novel TRPV4 agonist or antagonist templates were reported and the first selective TRPV4 antagonist was evaluated in early clinical trials.
Collapse
Affiliation(s)
- Brian G Lawhorn
- Medicinal Chemistry, Medicine Design, and Early Development Leaders, Research, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, United States.
| | - Edward J Brnardic
- Medicinal Chemistry, Medicine Design, and Early Development Leaders, Research, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, United States
| | - David J Behm
- Medicinal Chemistry, Medicine Design, and Early Development Leaders, Research, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, United States
| |
Collapse
|
4
|
Brooks CA, Barton LS, Behm DJ, Brnardic EJ, Costell MH, Holt DA, Jolivette LJ, Matthews JM, McAtee JJ, McCleland BW, Patterson JR, Pero JE, Rivero RA, Roethke TJ, Sanchez RM, Shenje R, Terrell LR, Lawhorn BG. Discovery of GSK3527497: A Candidate for the Inhibition of Transient Receptor Potential Vanilloid-4 (TRPV4). J Med Chem 2019; 62:9270-9280. [PMID: 31532662 DOI: 10.1021/acs.jmedchem.9b01247] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
GSK3527497, a preclinical candidate for the inhibition of TRPV4, was identified starting from the previously reported pyrrolidine sulfonamide TRPV4 inhibitors 1 and 2. Optimization of projected human dose was accomplished by specifically focusing on in vivo pharmacokinetic parameters CLu, Vdssu, and MRT. We highlight the use of conformational changes as a novel approach to modulate Vdssu and present results that suggest that molecular-shape-dependent binding to tissue components governs Vdssu in addition to bulk physicochemical properties. Optimization of CLu within the series was guided by in vitro metabolite identification, and the poor FaSSIF solubility imparted by the crystalline properties of the pyrrolidine diol scaffold was improved by the introduction of a charged moiety to enable excellent exposure from high crystalline doses. GSK3527497 is a preclinical candidate suitable for oral and iv administration that is projected to inhibit TRPV4 effectively in patients from a low daily clinical dose.
Collapse
Affiliation(s)
- Carl A Brooks
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - Linda S Barton
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - David J Behm
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - Edward J Brnardic
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - Melissa H Costell
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - Dennis A Holt
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - Larry J Jolivette
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - Jay M Matthews
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - John J McAtee
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - Brent W McCleland
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - Jaclyn R Patterson
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - Joseph E Pero
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - Ralph A Rivero
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - Theresa J Roethke
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - Robert M Sanchez
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - Raynold Shenje
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - Lamont R Terrell
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| | - Brian G Lawhorn
- Heart Failure Discovery Performance Unit and Flexible Discovery Unit , GlaxoSmithKline , Collegeville , Pennsylvania 19426 , United States
| |
Collapse
|